Vor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 464,421 Shares

Key Points

• Reprogrammed Interchange LLC, a major shareholder of Vor Biopharma, sold 464,421 shares on September 8 for approximately $924,197, resulting in a 1.31% decrease in their ownership.
• The stock price of Vor Biopharma has recently declined, closing at $1.80 on Wednesday, with a significant trading volume of over 6 million shares.
• Hedge funds have been increasing their positions in Vor Biopharma, with institutions owning 97.29% of the stock, indicating strong institutional interest despite recent shareholder sales.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 464,421 shares of the company's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $1.99, for a total value of $924,197.79. Following the transaction, the insider directly owned 35,012,518 shares of the company's stock, valued at $69,674,910.82. This trade represents a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 350,000 shares of Vor Biopharma stock. The shares were sold at an average price of $1.82, for a total value of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 449,226 shares of Vor Biopharma stock. The shares were sold at an average price of $2.00, for a total value of $898,452.00.
• On Friday, September 5th, Reprogrammed Interchange Llc sold 400,000 shares of Vor Biopharma stock. The shares were sold at an average price of $1.97, for a total value of $788,000.00.
• On Thursday, September 4th, Reprogrammed Interchange Llc sold 453,016 shares of Vor Biopharma stock. The shares were sold at an average price of $1.93, for a total value of $874,320.88.
• On Wednesday, September 3rd, Reprogrammed Interchange Llc sold 554,612 shares of Vor Biopharma stock. The shares were sold at an average price of $2.00, for a total value of $1,109,224.00.
• On Thursday, August 28th, Reprogrammed Interchange Llc sold 806,351 shares of Vor Biopharma stock. The stock was sold at an average price of $2.01, for a total value of $1,620,765.51.
• On Wednesday, August 27th, Reprogrammed Interchange Llc sold 611,647 shares of Vor Biopharma stock. The stock was sold at an average price of $2.01, for a total value of $1,229,410.47.
• On Tuesday, August 26th, Reprogrammed Interchange Llc sold 284,190 shares of Vor Biopharma stock. The stock was sold at an average price of $2.08, for a total value of $591,115.20.
• On Monday, August 25th, Reprogrammed Interchange Llc sold 387,346 shares of Vor Biopharma stock. The stock was sold at an average price of $2.12, for a total value of $821,173.52.

Vor Biopharma Stock Down 6.0%

VOR traded down $0.11 during trading on Monday, reaching $1.64. The stock had a trading volume of 3,922,454 shares, compared to its average volume of 7,605,040. Vor Biopharma Inc. has a 1-year low of $0.13 and a 1-year high of $3.29. The stock has a 50 day moving average of $2.12 and a two-hundred day moving average of $1.13. The firm has a market capitalization of $207.13 million, a price-to-earnings ratio of -0.99 and a beta of 2.05.

Institutional Investors Weigh In On Vor Biopharma

A number of hedge funds have recently bought and sold shares of VOR. Two Sigma Investments LP lifted its stake in shares of Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after buying an additional 25,930 shares during the period. Money Concepts Capital Corp boosted its position in shares of Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after purchasing an additional 26,535 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Vor Biopharma during the second quarter worth $66,000. Northern Trust Corp lifted its position in Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock valued at $175,000 after acquiring an additional 44,252 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after buying an additional 58,247 shares during the last quarter. 97.29% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $3.00 price objective on shares of Vor Biopharma in a research report on Thursday, August 14th. Wedbush reissued an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $6.07.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.